Monday, 17 July 2017

BioLargo’s Clyra Medical Subsidiary on Track to File 510K with FDA for Novel Wound Care Products



Tamarack Advisers recently published an article focused on Clyra Medical Technologies' exciting presentation at the Peter Sheehan Wound Healing: Science & Industry Conference in San Juan, Puerto Rico. 

______________________________________________________

A year and a half ago, BioLargo, Inc. (OTC: BLGO) announced that its Clyra Medical division secured financing to advance its novel wound care products.  Steve Harrison, President of Clyra Medical Technologies, then commented, "We believe this financing will provide the capital needed to help Clyra secure the regulatory approvals and launch what we believe will become a game changer for the Advanced Wound Care industry. This is a fast-growing $8 to $10 billion market in which we believe we will be able to offer better and more cost-effective solutions.”





Last month, Clyra Medical presented their breakthrough products at the 15th annual Peter Sheehan Wound Healing: Science & Industry Conference in Puerto Rico that was attended by leading wound care clinicians and researchers. We had a chance to speak with Mr. Harrison who reported, “We are highly encouraged by the overwhelming positive response from the clinical wound care experts attending the conference.  The data from the FDA pre-submission testing generated a great deal of enthusiasm among the leading clinicians and researchers at the conference.  The required pre-submission studies were conducted by Nelson Labs, an independent third party that is recognized as one of the leaders in laboratory testing for FDA submissions.”


The presentation at the conference highlighted Clyra’s advantages over existing wound care products:

  • Clyra’s hydrogel wound dressings and wound wash are highly effective and have no known antimicrobial resistance
  • GLP lab studies demonstrated sustained release and continued antimicrobial effectiveness against major organisms
  • Effective against biofilm in laboratory controlled in vivo pig studies has shown effectiveness against mature biofilm, with better results than certain prescription antimicrobial solutions
  • Non cytotoxic, non-sensitizing, and safe to human cells
  • Can easily integrate Clyra technologies into existing products and new ones in the pipeline including regenerative tissue
 
Dr. Brock Liden, DPM, a wound care expert with an extensive wound and limb salvage practice in Ohio presented the latest Clyra data to the conference. He commented “When I was introduced to the Clyra technology I was very interested to learn more. This is a complex that has been shown to impact bacteria, and show sustained activity, yet be safe to cells and the wound healing process. It may have clinical application to be used with cellular tissue products, stem cells, and growth factors with no harm to the modality. This is a significant breakthrough in the wound space. With further clinical research we may even have a modality to impact established biofilms while doing no harm to the host or the healing modalities being utilized.  As I learn more about Clyra’s technology, I feel that it has the potential to have a significant impact in wound care as well as potential in other areas of medicine”


On the flip side of their enthusiasm is that Clyra is keenly aware of the stiff competition they will face in the wound care industry.  One established competitor offering a broad line of wound care products is Smith & Nephew (NYSE: SNN).  Another is Osiris Therapeutics (NASDAQ: OSIR) that offers regenerative medicine products for difficult to treat acute and chronic wounds.

Clyra has retained Emergo, a global firm specializing in medical device regulatory consulting, to prepare its FDA filings, and reports they are on track for filing in the very near future. With the relatively short turnaround times for 510k submissions and the ongoing need for better wound care products, it is possible that Clyra’s powerful, gentle and long-lasting products may soon find themselves entering the rewarding stage of commercialization.

** Corrected Version 7-18-2017

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

SOURCE: Tamarack Advisors
 
For a link to the original article go here!

Tuesday, 27 June 2017

BioLargo Signs "National Purchasing Agreements" with Three Top Waste Industry Leaders

DENVER, CO / ACCESSWIRE / June 27, 2017 / With population density and urbanization increasing around the world, the need for cost-effective industrial odor control has become an even greater priority, and the problem has largely gone unsolved by the traditional suppliers. Historically, the available solutions have not satisfied users because most products only mask foul odors with heavy fragrances rather than eliminating the odors. Leading waste handling companies have been struggling with industrial odors for decades, believing there was no cost-effective solution that truly works. The only true solution is a product that will mitigate waste-related odors by actually eliminating the odor-causing compounds, and doing so without breaking the bank. Until now, no such product has been on the market.
Recently, a new product is gaining traction among leading waste handling companies that may change the paradigm: CupriDyne® Clean Industrial Odor Eliminator, made by Odor-No-More, Inc., a subsidiary of BioLargo, Inc (BLGO). The company claims CupriDyne Clean "actually works" by eliminating odors, rather than masking them with fragrances. The product has been proven effective against the nasty odors created at all types of facilities that handle and process our trash - from the trash trucks that haul it, to the "transfer stations" that sort it, and at the landfills, composting centers, and recycling operations where it ends up. From a scientific perspective, CupriDyne Clean oxidizes odors such as hydrogen sulfide, ammonia, mercaptans, fatty acids, sulfur compounds, and VOC's (volatile organic compounds). It can even be delivered fragrance-free since it does not rely on any sort of masking strategy.
In the past few weeks BioLargo's subsidiary Odor-No-More has signed what are known as national purchasing or national supply agreements with three leading US waste handling companies; an interesting development given that they started selling the product a year ago and had since not reported major advances in sales. In an audio interview with SNNLive posted on the BioLargo blog a few weeks ago, BioLargo's president described the signing of these national agreements as breaking a "barrier to entry". According to their SEC filings the agreements do not guarantee any volume of sales, but they do put the company in the system of a large company as an approved vendor, allowing the local facilities to easily order product and get their account serviced, without having to secure payment or deal with new contracts. And, according to Calvert, the agreements allow them to approach a facility, explain the product has been reviewed and approved by corporate and been evaluated for safety, and that other company facilities are using it with success. Doing business with a larger company can have its challenges, and 'corporate approval' in agreements like these, would be a major gateway to sales in any industry. Calvert believes sales will continue to grow and have the potential to increase "significantly", calling 2017 a "breakthrough year".
In addition to the news about these national agreements, BioLargo has also recently reported additional scientific breakthroughs in its clean water treatment technology the AOS (Advanced Oxidation System), and that the company is on the verge of filing for an FDA approval for its advanced wound care products through its subsidiary Clyra Medical Technologies. In any event, the market should respond positively as sales figures climb.
In BioLargo's April 25, 2017 trade release to industry at WasteExpo 2017, it disclosed the first national agreement, with Waste Connections, Inc., a multi-billion dollar company operating in 39 states. It announced a second national agreement in an interview on May 22, and then later identified the customer as Waste Industries USA, another top 10 U.S. company. At BioLargo's annual stockholder meeting on June 19th, they announced a third arrangement with another top 10 company but refused to disclose its identity. In a recent letter to BioLargo stockholders, Calvert reported, "We are now servicing 3 of the top 10 companies in the waste handling industry," and confirmed that sales are growing.
While the waste handling industry is certainly a prolific consumer of industrial odor control products, the need for such products extends into other large industries such as wastewater treatment, livestock and poultry production, food processing, composting and more. In fact, across these industries there are over one million industrial facilities with serious and chronic odor control challenges.
U.S. Industries that generate industrial odors
  • Approximate # U.S. Operations
  • Solid waste facilities - 15,740
  • Waste to energy plants - 300
  • Cattle and calf operations - 915,000
  • Poultry farms - 233,770
  • Meat & poultry slaughtering plants - 6,278
  • Hog farms - 12,200
  • Publicly operated wastewater plants - 14,780
Total U.S. Industrial Facilities - 1,198,068
Regardless of how large the market need is, the big question is: how much of this large market can be won by a "disruptive" new product, categorically superior to competitors? BioLargo has reported in its market analyses that the facilities they target could use anywhere from $2,000 to $20,000 per month in odor control products, although weather and temperature may have an impact on the need to control odor at any one facility. Hypothetically, if CupriDyne Clean captured 10% of the market in the solid waste facilities business alone, at a gross revenue per month of $2,000 that would equate to approximately $36 million in annual sales. There's no way to know what market share they will eventually capture. Sales should be ramping up as a result of breaking through the barriers and everyone, including management, will be anxious to see the results come in. The three recent national agreements are certainly a good sign for BioLargo's commercial future.
There appear to be a few big competitors in the industrial odor control market like ProSweet by General Electric (GE), and Versene by Dow Chemical (DOW) but apparently none perform like CupriDyne® Clean.
With all the excitement surrounding these recent developments, Calvert was quick to point out in a recent meeting at LD Micro that "Odor-No-More's continued success in this market will require careful attention to product support and customer service." Calvert added, "We love our customers, we offer exceptional service and, our CupriDyne Clean Industrial Odor Eliminator actually works."
Legal Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.
SOURCE: Tamarack Advisors

Monday, 26 June 2017

Developing Clean Water, Clean Air, and Advanced Wound Care Technologies, BioLargo, Inc. Focuses on Products that Improve Quality of Life


CEO/CFO Magazine Interview
Dennis P. Calvert
President, Chief Executive Officer
and Chairman of the Board

BioLargo, Inc. 
(OTCQB: BLGO)

Interview conducted by:

CEOCFO: Mr. Calvert, the BioLargo tagline is “We Make Life Better.” Would you tell us how you do that?
Mr. Calvert: The company has been inventing technologies and products for about ten years. Our primary focus is in the areas of clean water, clean air, and advanced healthcare. Our technologies were all designed and developed with the singular goal to improve quality of life in some way in their respective field and we believe they are all technical breakthroughs that can improve quality of life in many areas and for many people.

CEOCFO: How do you decide what to bring into the fold?
Mr. Calvert: We work hard to focus on important technical advances that are purposeful and valuable to make life better. We only invest in products that have the potential to become known as the #1 technical performer in their respective markets. However, innovation does involve risk. In order to pick winning opportunities, the first thing we do is conduct substantial market research to look for areas or challenges that are not well-served by existing products or technologies. Secondly, we look for margins – a place where innovation can be awarded so that as you find market traction, there are sufficient margins to pull and drive the risk and cost of innovation, because the R&D budget and time commitment to develop these products is very significant. Additionally, we are also coming into crowded marketplaces typically dominated by very large companies, so we look for the area in which we can find access to the market, whether by relationship or distribution channel or through a partnership. Our motto for our development cycle is that we invent, we prove, and we partner. At the end of the day, most of the market adoption that we enjoy is through partnerships with companies and people that already serve well-established marketplaces.

CEOCFO: Would you tell us about the products that you have available now?
Mr. Calvert: Our advanced water treatment technology is called AOS (Advanced Oxidation System), and the research and development work for this product has now received approximately thirty-five grants. It is in the Alpha prototype stage and heading into Beta stage, and was developed in conjunction with a number of industry leaders and researchers at the University of Alberta. The AOS represents a technical leap forward in the way we can treat contaminated water, and its primary value proposition is that it performs superior disinfection and decontamination, with an emphasis on soluble organics. The remarkable characteristic that gets everyone’s attention is its highly efficient performance and incredibly low electricity consumption, which translates to low cost. Its technical efficacy is now proven, and we are now heading into the scale-up and engineering effort for large scale commercial uses.

CEOCFO: How does AOS work?
Mr. Calvert: The discovery is that we can take low levels of electrical energy and combine it with an oxidant (iodine) at a low dose in a special carbon bed, resulting in highly efficient water disinfection/decontamination. Because of the way our system is configured, we actually generate what is called “super-oxides”, which are incredibly high-energy oxidative molecules, across the length of a filter apparatus made of carbon materials. The key to our discovery is that we can generate super-oxides while requiring incredibly low electrical energy levels, and the oxidation potential we generate is an order of magnitude higher than was previously known possible with electrochemical systems. 

CEOCFO: How is this used?
Mr. Calvert: The water industry is a behemoth at approximately $850 billion annually. In principle, our technology could have application in just about every sector of the water industry. Our focus at the moment is on picking the market where we believe we can win and where there are margins that sufficiently award innovation, and where we have relationships and access to the marketplace. We are focused right now in the food and beverage sector with an emphasis on processing wastewater. In this application, it’s an incredibly difficult, technical, and costly challenge to clean up contaminated wastewater, and the food and beverage industry is facing increasing pressure to deal with their waste streams. Existing water treatment platforms are not serving this market need sufficiently, which spurred us to focus our efforts in this area. We have a number of relationships in this industry; in fact our research center is located at Agri-Food Discovery Place at the University of Alberta. As a result of those key relationships, we have access to expertise, potential customers, collaborators and leading researchers. While this area is our first focus, we believe eventually that our technology will find its way into just about every segment of the water market. 

CEOCFO: What else is going on at BioLargo?
Mr. Calvert: We have two other key product lines: one is our industrial odor control product, CupriDyne Clean, which is now finding rapid adoption in the waste handling and wastewater treatment industries. We recently signed three national contracts with leading companies that serve the waste industry and we believe we are going to get all the major industry leaders. In this application, we are delivering liquid chemistry to solve odor control challenges through misting systems, and also water delivery systems like water trucks and spray apparatuses. CupriDyne Clean is being used to oxidize odorous compounds that are the natural byproduct of waste, but that cause the waste handling industry substantial grief. These compounds include ammonia and H2S, and other sulphur compounds, as well as mercaptans and fatty acids. Waste handling and wastewater treatment facilities are a primary target and we have chosen to target national corporate accounts. We have secured three national contracts in the last six weeks. The product is effective, safe, easy to use and affordable. We believe we are going to land contracts with all of the industry leaders.

CEOCFO: Why is now the time?
Mr. Calvert: CupriDyne Clean was first launched in May of 2016, and the science was first developed and refined for consumer product applications. Our consumer products won all sorts of praise and acclaim, including four “product of the year awards” in the pet and companion animal industry, but those consumer products have not yet found a meaningful channel for distribution. About a year and a half ago, as a result of my relationship as board member of SustainOC.org, an industry trade group based in Southern California, we had a chance to meet one of the regional vice presidents at one of the largest waste handling companies in the world. He urged us to consider taking the technology into a development cycle to serve the national waste handling industry, which is commonly referred to as industrial odor control. That led to trials, which were exceptional, and we were even congratulated as having a “revolutionary” technological advance for the waste handling industry – this was a little over a year ago. Since then we have invested in becoming familiar with and learning that industry, working with top management, and developing both top-down and bottom-up marketing strategies. CupriDyne has been serving the industrial odor control industry in the field for about a year now, and we just have recently broken through a significant barrier to entry by securing those national accounts, and now we’re selling product to many of the largest companies in the waste handling industry.

CEOCFO: Do you have a third area of focus?
Mr. Calvert: One of our technologies is organized in a subsidiary named Clyra Medical Technologies, and it is focused on developing and commercializing a series of advanced wound care products. In that company, we recently brought in a strategic investor who invested about $1 million over the past year. We then invested to recruit the best talent possible –  leaders from the industry and well-entrenched specialists – to develop a series of advanced wound care products. As a result of all that work, we believe we will be making FDA applications under 510(k) in the next few weeks for the first of these products. We believe these advanced wound care products will be highly disruptive for a very large, important and urgent need in the advanced wound care field. 

CEOCFO: Why has it been so hard to find a way to treat chronic wounds?
Mr. Calvert: Chronic infected wounds are often the result of suppressed immune systems, and typically occur with senior citizens who commonly suffer from poor circulation and/or diabetes. The nature of these wounds makes them extremely difficult to manage. When it comes to treating and healing those wounds, the industry is continually seeking new and improved technical solutions. Silver compounds historically had the largest market share, however, these compounds are coming under increased scrutiny for their potential to cause microbial resistance and, as one might imagine, they can be very expensive. There are a number of iodine-based products that have done well, but the traditional iodine products on the market are often considered cytotoxic, and they often cause staining and are difficult to work with. They are quite effective as disinfectants, but they also had a potential to cause tissue damage and in some cases inhibit scar formation. Physicians and patients have therefore been forced to accept side effects for the sake of efficacy. These dynamics and the obvious need for improvement create a market gap for an antimicrobial strategy with no known acquired resistance that is gentle and at the same time helps promote rapid healing. This is where our Clyra Medical Technologies will shine. Our products are proven effective in the disinfection of a broad array of pathogens and include ingredients that are naturally accepted by the body and have well-established metabolic pathways. We have successfully passed the required Cytotox and sensitivity testing. We also believe some of our ingredients will be highly effective in helping the body form scar tissue. We also have evidence to support their potential role to help manage biofilms. The combination of all these features gives our subsidiary Clyra Medical Technologies a significant competitive edge in a highly competitive and highly technical market. There is a market gap, and we intend to fill that gap with these products.

CEOCFO: What are the challenges as CEO with so much happening at one time?
Mr. Calvert: In each of these product lines we have actually formed companies and recruited specialists to guide us as we fully develop these technical products and platforms. We invent, prove and partner. In all of these situations we believe the ultimate outcome will be for these products to find their way into partnerships by licensing and joint venturing. We are exceptionally good at the inventing and proving side. However, it would be difficult to manage the full execution of all of these products to a full-scale commercial level. For example, if we look at our wound care technology, it presents itself into a perfect spinoff into its own company, and we intend to pursue that when it is ready. In other situations, like our industrial odor control product, we are taking the product directly to market through our wholly owned subsidiary Odor-No-More. The water technology is so big that we believe multiple partnerships will present themselves across the various industry segments. 

CEOCFO: What has changed in your approach over time?
Mr. Calvert: Over time we have become increasingly more discerning and selective as to where we choose to invest our time, energy and money. We seek opportunities where we can succeed and where there is a previously unidentified solution to a problem. Over time we have become highly skilled at that. As a result of the refinements and technical advances, we are finding success. We know that proper capitalization and finding the right talent are ever so critical. We are becoming increasingly skilled at making sure that both of those key pieces of the puzzle are in place to execute a successful commercial strategy. Relative to the opportunities in the general marketplace, we see problems associated with microbial control, increasing urbanization, consolidation of industry, and so on. If you think of it at the highest level, and look at the nature of air and water and healthcare, they all face problems that are a direct result of concentration and vacuums – this idea that with highly industrialized waste streams, highly concentrated urban density, we often overload the system with microbial threats and the problems require technological innovation to overcome them efficiently and cost effectively.

CEOCFO: Has the investment community been paying attention?
Mr. Calvert: We have a significant group of investors that have supported our business. Our total invested capital is about $20 million since we began this journey in 2007. We are beginning to capture early-stage institutional investor’s attention and we are anxious to take the company into a national market when ready. We also are now at the point where we are finding commercial traction in very large markets with substantial upside. That is new and certainly increases our exposure. Our company has an important piece of the puzzle to help make life better in a few of the most critical markets known, water, air and healthcare. The marketplace has not fully recognized that yet, but it will!

CEOCFO: What might be missed about Biolargo at first look?
Mr. Calvert: As a science and technology-based company, it is difficult for the average onlooker to fully appreciate the significance of our technical advances. It takes discernment and digging in. When people dig deep they tend to be  quite astonished. The innovation behind BioLargo is the culmination of our founder and Chief Science Officer Ken Code’s life’s work. I can’t imagine a more meaningful legacy. Everything that we do represents a significant technical leap forward and that is not necessarily easy to identify for the average investor. As a result, unfortunately, many investors might wait for commercial success. Those who recognize the significance of our technical advances often become our investors. As hard as it might be to pick a winner before commercial success is fully realized, we know that BioLargo’s sustainable technologies will become recognized around the world to help make life better as we deliver clean water, clean air and advanced healthcare as the low cost and high impact solution provider.

Of course, we remind everyone to study our Annual Report and Quarterly Report’s at www.sec.gov for complete disclosure the various risk factors and financial condition of the company as they evaluate our business.

Wednesday, 21 June 2017

BioLargo Subsidiary Odor-No-More Signs National Purchasing Agreement with Waste Industries USA

More great news this week, as BioLargo subsidiary Odor-No-More announced that the company had signed a National Purchasing Agreement with another top 10 US waste handling company, Waste Industries USA, for Odor-No-More's CupriDyne Clean Industrial Odor Control Solution (www.cupridyne.com).

Odor-No-More put out a press release on Waste Advantage announcing this contract, where Waste Industries Purchasing Manager Josh Thompson was quoted, "A number of our sites tested Odor-No-More’s products, and the results were remarkable. Not only did they like the product, they were impressed with the quality of service from the company".

CupriDyne Clean makes it Cleaner!  

For more info, read the press release on Waste Advantage.

Tuesday, 20 June 2017

President and CEO’s report of BioLargo 2017 Annual Stockholders’ Meeting


Dear BioLargo Stockholders,

We had a great meeting yesterday (June 19th) at our corporate offices in Westminster California. If you were unable to attend, we missed you and we encourage you to attend in the future. Of course, we also encourage you to reach out to us anytime to discuss our status and progress. It was so good to reconnect with old friends and share our team’s enthusiasm for BioLargo and our mission to make life better. 

The business of the meeting was successfully accomplished. All recommendations presented to the stockholders were approved. During a discussion of business progress, we provided insights about a series of important commercial milestones, and helped explain why we believe the future remains so bright for BioLargo. Here are a few highlights:
  1.  Jack B. “Jay” Strommen has officially joined our Board of Directors . He plays a critical role with BioLargo as an investor, partner, and financier of our subsidiary Clyra Medical Technologies. He is a winner and a strong addition to our team, and on behalf of the company we thank him for his hard work. 
  2. We want to take a moment to thank Gary Cox for his years of dedicated service as a Board Member at BioLargo that ended yesterday. We look forward to pursuing new business relationships together in the future. 
  3. We reviewed our presentation given at the 7th Annual LD Micro Invitational conference on June 6, 2017 (linked here), which provided a comprehensive overview of our progress, our milestones, and our near term and long term goals. 
  4. We shared the news (linked here) about our increasing sales of our CupriDyne Clean Industrial Odor Control products,  nd that we expect these sales to continue to increase due to the very recent execution of “National Purchasing Agreements” with two of the top 10 waste handling companies in the industry, as previously announced, providing us vendor status that allows us to sell to the local facilities of these large companies. We also shared new information that we have just entered into a similar contractual relationship with another top industry member. We are now servicing three of the top 10 companies in the waste handling industry. These agreements demonstrate that we are breaking through the significant barriers-to-entry for this market, and are a testimony to the now-recognized superior quality of our products, as well as the continuing commitment of the team at our subsidiary Odor-No-More, Inc. to support these very important customers. As our satisfied customers say, “Finally, an industrial odor control product that actually works”. Stay tuned for more information as we advance sales! 
  5. We enjoyed an update from Mr. Steve Harrison, President of our subsidiary Clyra Medical Technologies, on his plan to file a 510(k) application with the FDA very soon. With the support of a $1 million investment from the Strommen family made over the past year, we were able to develop an advanced wound care product for topical use on chronic infected wounds, and a dental product that can help patients avoid post-surgical infections. We believe these two products set the stage to build a portfolio of products to serve these important markets. Mr. Harrison reported that the first public presentation about our products will be made later this week at the Annual Wound Healing: Science and Industry Conference (WoundHSI), sponsored by the Peter Sheehan Diabetes Care Foundation (http://www.woundhsi.org). Our products will be highlighted in a presentation by a leading professional in the field, Dr. Brock A. Liden, DPM, titled Anti-Infective and Biofilm Therapy. 
  6. We updated the attendees on the advancing discussions with potential engineering scale-up partners, potential commercial partners, and public funding sources for our AOS clean water technology. As you may recall, we have proven the science behind the AOS, and have developed its water disinfection and decontamination thoroughly in the lab. We are now heading from the “Alpha” prototype to a “Beta” prototype, and subsequently to commercialization. The science of this technology is advancing and gaining international acclaim, and we look forward to sharing more details as we prepare for our 3rd annual technical symposium in August.
Before I close, I want to take a moment to remember one our original team members, Mr. Jeffrey Wallace, who recently passed away. Jeff was critical part of the early days of organizing BioLargo into what it has become today. He was a GREAT man that invested his life serving others. As a man of integrity, he mentored more than 50 Eagle Scouts in the Boy Scouts of America program and he left a lasting mark in this world for all things good and right. We will miss Jeff and pray for his family in their loss. Amen.

2017 is the break-through year for BioLargo and we are thankful for your continued support. 

Stay tuned as we march forward in our mission to make life better!

Dennis P. Calvert
President & CEO
BioLargo, Inc.
June 20, 2017

#GoBioLargo #GoOdor-no-more 


Cautionary note regarding forward-looking statements.

All statements, other than statements of historical fact, included in this correspondence regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements. We have included important risks and uncertainties in the cautionary statements included in our annual report on Form 10-K, particularly the section titled “Risk Factors”, incorporated by reference herein. We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. Our forward-looking statements do not reflect the potential impact of future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this correspondence may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Any forward-looking statement made by us in this correspondence is based only on information currently available to us and speaks only as of the date on which it is made.

widget